Abstract
Purpose :
The study aimed to analyze and quantify the levels of inflammatory cytokines and adhesion molecules that actively participate in the inflammatory response of patients diagnosed with PP in comparison with a control group.
Methods :
A transversal case-control study included 40 patients (20 patients with PP and 20 patients with vitrectomy for another cause), from whom a vitreous tap was obtained by vitrectomy. The quantification of cytokines using Luminex Multiplex systems and ELISA assays.
Results :
The median age for de control group was 64 years (ICR 55-72) and a median of 11 years (ICR 8-14) for PP patients. Gender prevalence in PP patients was 75% male (n=15) and 25% (n=5) female patients. The molecular data showed an increase in the median of E-selectin, I-CAM, IL-2, IL-6, IL-8, and IP-10 in the PP group. The values obtained to compare the controls vs PP patient for FGF-b 4.32pg/mL(ICR 0.64-7.27), IL1b 0.40 pg/mL (0.14-0.49), G-CSF 25.87 pg/mL (0.001-45.14), IL-10 0.001 pg/mL (0.001-0.001), IL-13 4.52 pg/mL (2.57-4.96), IL-6 25.78 pg/mL (15.28-127.35), IL-12 7.94 pg/mL (5.22-11.71), RANTES1 5.43 pg/mL (0.001-9.84), EOTAXIN 2.43 pg/mL (2.43-2.43), IL17A 0.001 pg/mL (0.001-0.001), MIP1a 0.001 pg/mL (0.001-0.001), GM-CSF 0.001 pg/mL (0.001-2.27), MIP1b 42.15 pg/mL (39.36-45.97), MCP1 687.74 pg/mL (269.43-1581.78), IL-15 0.001 pg/mL (0.001-25.40), EGF 19.09 pg/mL (9.37-30.73), IL-5 5.27 pg/mL (3.17-6.32), HGF 1687.02 pg/mL (913.46-4131.34), VEGF 7.80 pg/mL (6.60-8.92), IFNγ 0.39 pg/mL (0.09-1.07), IFNa 2.72 pg/mL (0.001-8.56), IL1RA 22.10 pg/mL (8.06-46.24), TNFa 1.81 pg/mL (1.20-2.92), IL-7 0.001 pg/mL (0.001-0.001), IP-10 13.20 pg/mL (1.51-32.70), IL-2R 0.001pg/mL (0.001-4.02), MIG 29.81 pg/mL (25.00-34.46), IL-4 5.40 pg/mL (3.97-588), IL-8 27.18 pg/mL (8.66-74.79), I-CAM 2325.08 pg/mL (1.56-11932.70), E-Selectin 0.78 pg/mL (0.78-0.78), P-Selectin 2723.11 pg/mL (1008.29-4112.08). The analysis showed statistical significance (p<0.05) for E-selectin, IL-6, and IP-10 cytokines using the Wilcoxon test.
Conclusions :
In conclusion, patients with PP showed a Th1 profile on the vitreous. This knowledge could help in the development of new therapeutic approaches and new intraocular treatments in the future.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.